News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) to conduct investor webcast on November 13, 2024 at 8:30 a.m. Eastern to review Q3 2024 financials and provide corporate updates -
-
-
COMMUNIQUÉ DE PRESSE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. announces FDA conditional approval renewal of Canalevia-CA1 for chemotherapy-induced diarrhea in dogs. Canalevia-CA1, a crofelemer tablet, is available from major U.S. veterinary distributors -
-
-
COMMUNIQUÉ DE PRESSE
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals announces acceptance of late-breaking abstract on crofelemer results for breast cancer patients in OnTarget trial, presented at SABCS 2024
